VESSL Therapeutics
Developer of autologous cell- and gene-based therapies for vascular-related conditions. The company isolates a patient’s endothelial cells from a short vein segment, modifies them with angiogenic genes ex vivo, and reintroduces them to promote blood-vessel formation or to line biosynthetic vascular grafts. Lead programs target peripheral artery disease and hemodialysis vascular access; preclinical work and early-phase clinical studies have been completed and further clinical progression is planned.
Industries
Nr. of Employees
small (1-50)
VESSL Therapeutics
Colab Square Facility, 6 HaYozma Street, Yokneam Illit 2069203, Israel
Products
MultiGeneAngio (autologous cell and gene therapy) for peripheral artery disease
An autologous cell-and-gene therapy that uses a patient’s endothelial cells modified ex vivo with angiogenic genes to enhance collateral artery formation and improve limb perfusion in advanced PAD/critical limb ischemia patients.
MultiGeneGraft (biosynthetic vascular graft lined with autologous cells)
A biosynthetic arterio-venous graft lined with a patient’s own gene-modified endothelial cells intended for hemodialysis vascular access to improve graft biocompatibility and durability.
Platform programs in preclinical development
Platform-derived programs under preclinical development include coronary artery disease therapy, liver regeneration therapy, and ocular therapy for diabetic retinopathy.
MultiGeneAngio (autologous cell and gene therapy) for peripheral artery disease
An autologous cell-and-gene therapy that uses a patient’s endothelial cells modified ex vivo with angiogenic genes to enhance collateral artery formation and improve limb perfusion in advanced PAD/critical limb ischemia patients.
MultiGeneGraft (biosynthetic vascular graft lined with autologous cells)
A biosynthetic arterio-venous graft lined with a patient’s own gene-modified endothelial cells intended for hemodialysis vascular access to improve graft biocompatibility and durability.
Platform programs in preclinical development
Platform-derived programs under preclinical development include coronary artery disease therapy, liver regeneration therapy, and ocular therapy for diabetic retinopathy.
Expertise Areas
- Autologous cell and gene therapy
- Therapeutic angiogenesis
- Vascular graft design and biomaterials
- Preclinical and early-stage clinical development
Key Technologies
- Endothelial cell isolation and culture from vein segments
- Ex vivo gene modification of primary vascular cells
- Angiogenic gene delivery
- Biosynthetic vascular graft fabrication and cell seeding
News & Updates
Preclinical experiments and two Phase I/IIa clinical trials treating 35 PAD patients were completed with no reported safety issues and early indications of efficacy.
Closed a $16 million financing round to advance development of cell and gene therapy programs and support regulatory activities.
Preclinical experiments and two Phase I/IIa clinical trials treating 35 PAD patients were completed with no reported safety issues and early indications of efficacy.
Closed a $16 million financing round to advance development of cell and gene therapy programs and support regulatory activities.